KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) FCF Margin (2017 - 2025)

Sarepta Therapeutics has reported FCF Margin over the past 12 years, most recently at 28.81% for Q4 2025.

  • Quarterly results put FCF Margin at 28.81% for Q4 2025, up 2062.0% from a year ago — trailing twelve months through Dec 2025 was 13.99% (up 403.0% YoY), and the annual figure for FY2025 was 13.99%, up 403.0%.
  • FCF Margin for Q4 2025 was 28.81% at Sarepta Therapeutics, up from 9.39% in the prior quarter.
  • Over the last five years, FCF Margin for SRPT hit a ceiling of 37.56% in Q2 2025 and a floor of 994.69% in Q1 2023.
  • Median FCF Margin over the past 5 years was 48.65% (2022), compared with a mean of 140.7%.
  • Peak annual rise in FCF Margin hit 110080bps in 2021, while the deepest fall reached -481483bps in 2021.
  • Sarepta Therapeutics' FCF Margin stood at 15.65% in 2021, then grew by 17bps to 12.92% in 2022, then soared by 47bps to 6.84% in 2023, then surged by 220bps to 8.2% in 2024, then soared by 252bps to 28.81% in 2025.
  • The last three reported values for FCF Margin were 28.81% (Q4 2025), 9.39% (Q3 2025), and 37.56% (Q2 2025) per Business Quant data.